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Abstract Human leukocyte antigen (HLA) sensitisation oc-
curs after transfusion of blood products and transplantation. It
can also happen spontaneously through cross-sensitisation
from infection and pro-inflammatory events. Patients who
are highly sensitised face longer waiting times on organ allo-
cation programmes, more graft rejection and therefore more
side effects of immunosuppression, and poorer graft out-
comes. In this review, we discuss these issues, along with
the limitations of modern HLA detection methods, and poten-
tial ways of decreasing HLA antibody development. We do
not discuss the removal of antibodies after they have
developed.
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Introduction
Antibodies to human leukocyte antigens (HLA) are an impor-
tant barrier to transplantation. When directed against donor
HLA they can cause acute graft rejection and chronic graft
nephropathy. HLA-sensitised patients may meet with difficul-
ty and delay in finding an HLA-compatible graft, leading to
longer waiting times on the transplant list. Their presence is of
particular importance in children, who are likely to need more
than one transplant in their lifetime.
Human leukocyte antigens and HLA sensitisation
The major histocompatibility complex (MHC) located on
chromosome 6 consists of a linked set of genetic loci contain-
ing many genes involved in the immune response, including
the HLA genes. The products of these genes are expressed on
the cell surface as glycoproteins, of which there are three
classes within the MHC region:
& Class I region, which includes the HLA genes HLA-A, -B
and -C, expressed on nearly all nucleated cells
& Class II region, which includes HLA genes HLA-DR, -
DQ and -DP only expressed on B cells, antigen-presenting
cells (APCs) and on activated endothelial cells (that can
act as APCs)
& Class III region, which includes the genes for components
of the complement cascade and cytokines, e.g. TNF, LTA
Antigen-presenting cells (APCs) are a group of cells that
process antigens and present them, in association with HLA
molecules, to T cells. CD4 Tcells (T helper cells) interact with
class II molecules, resulting in the production of cytokines that
lead to a cascade of cellular and humoral reactions that are
responsible for the effector responses important in transplant
rejection. CD8 T cells (T killer cells) are cytolytic, directly
interacting with cells expressing class I and maybe toxic to the
cell to which they bind.
Human leukocyte antigen antibodies can develop under
any circumstance of exposure to non-self HLA antigens. They
may be unique to a specific allele or limited group or recog-
nise an epitope that is shared by more than one HLAmolecule
resulting in cross-reactivity. The level of sensitisation (called
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reaction frequency [RF]) for a patient is calculated by finding
the percentage of blood group identical, HLA-incompatible
donors in the donor pool: i.e. if the patient’s serum reacts with
50% of a panel of sera that is representative of the donor pool,
then half of donors would be expected to give a positive cross-
match and be unacceptable. HLA antibodies therefore repre-
sent a serious obstacle to successful transplantation. Pre-
transplant identification of preformed HLA antibodies is es-
sential in order to predict whether a potential donor will be
HLA compatible and to avoid unnecessary consideration of an
inappropriate donor [1].
Modern methods of HLA antibody measurement: are we
measuring what we think we are?
Historically, the detection of HLA antibodies was based on
complement-dependent cytotoxicity (CDC), where sera were
incubated with a panel of cells with the addition of comple-
ment and the read out was cell lysis (Fig. 1) [2–5]. Sensitivity
for detecting antibodies is low, but the positive predictive
value for early antibody mediated rejection is high. The sen-
sitivity can be improved by using flow cytometry to detect the
bound antibodies. By concurrently staining for T-cells and B-
cells HLA class I and HLA class II respectively can be typed
[2].
Currently, HLA antibody screening is carried out on solid
phase assays either using HLA molecules bound to plates in
an ELISA system or more commonly polystyrene beads using
the Luminex platform [2, 3] (Fig. 1). Each bead is coated with
a single cloned recombinant HLA epitope. With the large
library of HLA alleles available, this has allowed for detection
of HLA antibodies across all 11 HLA loci, including rare
alleles in the population and the evaluation of complexly
sensitised sera down to the level of individual specificities
[2]. The ability to routinely test for HLA antibodies against
HLA-Cw, -DQA, -DQB, -DPA, and -DPB has also lead to a
greater appreciation of their role in chronic antibody-mediated
rejection post-transplant [2, 6].
The quantity of antibody is measured by the mean fluores-
cence intensity (MFI) of each bead corresponding to the level
of antibody bound. As there is large variability between labs
and even between tests done by the same lab, the MFI mea-
surement is only semi-quantitative [2]. This inherent variabil-
ity is due to the sensitive nature of the assay but can also be
due to differences between densities of the antigens on each
bead from different manufacturers. Even in the setting of a
study using a fixed protocol, variations of 25 % were found
[7]. In addition, antibodies to common HLA epitopes can give
artificially low MFI values if they bind to multiple beads
sharing similar epitopes, giving a large breadth of antigen
positivity but low MFI values [2]. The constructed recombi-
nant HLA allele on beads may not directly correspond to the
three-dimensional HLA structure in vivo on cell surfaces and
might not represent exposed epitopes [8]. In addition, false-
positive results can be obtained by binding of antibody to
denatured protein on the beads [9].
At a practical level, most laboratories use a combination of
cell based and solid phase assays. Pre-transplantation sera are
screened using HLA Class I and II panels. Positive results are
often confirmed using kits from separate manufacturers before
proceeding to specific HLA antibody typing using solid phase
assays. There are no fixed standard MFI thresholds that pre-
dict a positive CDC crossmatch and represent a contra-
indication to transplantation [2]. Interpretation of MFI values
must be made according to local guidelines in close collabo-
ration with HLA laboratories and take into account potential
past significant sensitisation events. Of note, certain therapies,
particularly immunoglobulin-based therapies such as pooled
IVIG, ATG, and rituximab will interfere with solid phase
assays [2]. The correct interpretation of HLA antibody screen-
ing is important to avoid disadvantaging recipients with pos-
itive results that might not be clinically significant.
Causes of HLA sensitisation
Human leukocyte antigen antibodies usually develop in asso-
ciation with exposure to non-self HLA molecules such as
blood products, foreign tissue during transplantation or during
pregnancy, but they can also develop spontaneously.
Blood products
Despite the availability of erythropoiesis-stimulating agents
(ESAs), anaemia remains a significant problem worldwide.
An analysis from the International Pediatric Peritoneal Dialy-
sis Network has shown that of 1,394 paediatric patients un-
dergoing peritoneal dialysis from 30 countries, 25 % of pa-
tients had haemoglobin levels below target (<10 g/dl or
<9.5 g/dl in children older or younger than 2 years respective-
ly) despite the prescription of ESAs to 92 % of patients [10].
These children are vulnerable to developing a blood require-
ment during acute illness; thus, optimisation of ESA therapy
may at least be able to prevent blood transfusion in these
patients. However, there remain situations when blood trans-
fusions cannot be avoided: for example, infants on
haemodialysis who need lines priming with blood; the child
with late presentation in chronic kidney disease (CKD) stage
5; in emergencies; or during surgical procedures.
The sensitisation risk from red cell transfusions is often
underestimated owing to the popular misconception that
erythrocytes (being enucleated cells) do not express HLA
molecules. In actual fact, erythrocytes express low levels of
HLA class I molecules, i.e. 100–2,000 per cell (compared to 1
−2×105 on leukocytes) [11, 12]. However, because of the
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large numbers of erythrocytes, HLA sensitisation would be
expected to occur. Several studies in the adult literature using
contemporary solid phase assay methods have confirmed that
blood transfusions induce or reactivate HLA allo-
immunisation [13–16]. The risk of sensitisation is proportion-
al to prior sensitisation events. Therefore, children with failed
transplants are at the highest risk of sensitisation, followed by
those who have received multiple transfusions [11, 17]. In a
study of male patients awaiting their first transplants, transfu-
sion with leukodepleted red blood cells was associated with a
relative risk of 4.1 of developing HLA antibodies compared
with non-transfused patients [15]. In another study of patients
on dialysis, transfused patients had an adjusted odds ratio of
9.6, even when applying a high positive criterion of MFI
>10,000. The risk remained even when patients with pro-
inflammatory events were excluded [16]. The risk of sensiti-
sation in paediatrics is less well characterised, although it is
reported that children are more likely to mount an alloimmune
response than adults [18]. Infants are a special group as they
are less likely to develop allo-sensitisation, even though they
need blood priming of haemodialysis lines [19]. In our centre,
1 in 7 (16%) developed HLA antibodies despite an average of
7.5 adult units per individual [19]. Some HLA antigens may
be more immunogenic than others, for example, HLA-A3,
A66, and B18 [20, 21]. In summary, red cells pose a signifi-
cant risk of HLA sensitisation, which is stratified according to
prior sensitisation events.
Other blood products that contain leukocytes or platelets
are also immunogenic, and are often needed alongside blood
in the sick child. Platelets in particular contain 81,587
(±20,016) HLA molecules per cell [22]. Platelet refractoriness
is a recognised complication of multiple platelet transfusions
in the setting of malignancies and often requires treatment
with HLA-matched platelets. The investigation of HLA sen-
sitisation in CKD patients who do not have such high platelet
requirements has not been published. Leukocytes, white cell
fragments, DNA, HLA peptides, cell debris and pro-
inflammatory cytokines that accumulate in the fluid suspen-
sion of the blood product during storage can all potentially
induce sensitisation with transfusion [23, 24].
Transplantation
Transplant programmes for children with CKD have been
very successful, with more children undergoing transplanta-
tion, and at progressively younger ages. Indeed, transplanta-
tion is generally considered to be the optimal management for
children needing renal replacement therapy (RRT). However,
despite improvements in outcomes over the decades, some
children will inevitably lose their transplants and require
relisting for repeat transplantation. Many of these children
will develop HLA antibodies, although antibodies do not
inevitably develop to every mismatched antigen [25]. Even
if patients are HLA-antibody-negative at the time of graft loss,
a proportion can subsequently become positive, usually owing
to cessation of immunosuppression or a triggering pro-
inflammatory event, including a blood transfusion [11, 26].
There has been a report of two patients who were initially
unsensitised, then developed HLA antibodies to the previous
transplant after transfusion but not towards the blood donor
[27].
Another group of children that is increasing in size and
complexity consists of those who have received transplants
for other organ failure. These patients often have renal dys-
function even before transplantation owing to co-morbidity
from their underlying condition and develop further
Fig. 1 Methods of human
leukocyte antigen (HLA)
antibody detection. Adapted from
Dheda et al. [4], originally
published under CC BY 3.0
license
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nephrotoxicity related to calcineurin inhibitor therapy [28].
The prevalence of HLA antibodies in these patients is high
and varies from 12 to 92% depending on organ type and study
[29]. HLA matching is often not performed in other solid
organ transplants as other factors often take priority, such as
size/weight and the lack of time to perform cross-matching in
order to reduce ischaemia–reperfusion injury [29, 30]. In
addition, cardiac patients have high HLA sensitisation levels
owing to large transfusion requirements peri-operatively and
the use of ventricular assist devices has also been linked to
HLA sensitisation [11]. In summary, transplantation of any
solid organs represent the largest sensitisation risk because of
the large antigen load. Efforts at prolonging allograft survival
will have a direct impact on HLA sensitisation and the need
for retransplantation.
Spontaneous development of HLA antibodies
Human leukocyte antigen antibodies have been detected in
patients without any known sensitisation events, and are
called “spontaneous” HLA antibodies. In a study of a paedi-
atric population of 23 children awaiting transplant who did not
receive blood products 26 % developed HLA antibodies over
a course of 19 months [19]. A recent large cross-sectional
study of UK adult male patients awaiting their first transplants
showed a sensitisation rate of 4.1 % [13, 20]. This could be
due to cross-sensitisation following infections, such as influ-
enza and hepatitis C [31–33]. Environmental factors such as
microorganisms, ingested proteins, and allergens have also
been proposed as potential causes of the variation in “sponta-
neous” HLA antibody detection rates, and allosensitisation
rates as high as 64 % have been detected in healthy adult
Mexican blood donating males [34]. Other pro-inflammatory
events such as operations and trauma have also been associ-
ated with an increase in HLA antibodies [35]. There has also
been concerns regarding the potent ia l for HLA
allosensitisation following vaccinations [33]. However, as
these studies were carried out using solid phase assays, the
clinical significance of the positive results is not well
established. In fact, the majority of the HLA antibodies de-
clined or disappeared on follow-up testing [11, 33]. This was
also the case in the study examining HLA sensitisation fol-
lowing H1N1 influenza vaccinations and patients could also
be allosensitised following actual influenza infection as it was
highly prevalent at the time of the study [33]. Other studies
examining HLA sensitisation after immunisation have not
shown an adverse effect [36, 37]. Therefore, established vac-
cinations remain recommended in children with CKD.
In summary, “spontaneous” HLA antibodies are likely
non-specific and arise from an upregulation of the immune
system from pro-inflammatory events. This is different from
the setting post-transplant, where infection is recognised to
trigger rejection episodes [38].
HLA sensitisation and organ allocation algorithms
worldwide
The predominant factor determining the incidence of HLA
sensitisation in any population is the transplant HLAmatching
policy, which varies around the world and even within the
same country: for example, in Belgium and Holland, HLA
matching schemes vary from acceptance of all mismatches to
a minimal match of 1A, 1B, and 1DR [39]. In the UK, the aim
of the allocation programme is to maximise outcomes and
minimise resultant sensitisation by the prioritisation of well-
matched transplants for younger patients [25]. In the USA the
transplant allocation policy favours reducing time on dialysis
over HLA matching [40].
Sensitisation increases in proportion to the number of HLA
mismatches that a patient is exposed to. It can occur even with
a zero mismatched graft, although only in up to 10 % of
patients in this group [5]. In the USA, up to 30 % of all
patients waiting for a renal transplant have a reaction frequen-
cy that is greater than 20% [41]. HLA sensitisation by blood is
also important. The United States Renal Data System
(USRDS) 2010 report has shown that patients who have
received transfusions have a 2.38 greater odds of a reaction
frequency >80 %. It would appear that the breadth and quan-
tity of HLA antibody development is the most severe in those
who are already sensitised [42].
Why is HLA matching important?
Effect on graft outcome
It has been argued that an HLA-matching policy extends time
on dialysis, with all its well-known adverse effects; that the
benefits of matching may be outweighed by prolongation of
the cold ischaemia time in organ sharing schemes that cover
large geographical areas; and that with the success of current
immunosuppression, HLA matching is not necessary [43].
Indeed, donor and recipient matching at the HLA-A and
HLA-B locus has been excluded in the USA from the kidney
allocation scheme because the benefits to survival were shown
to be small and to increase waiting times [44]. An analysis of
all first deceased donor transplants from donors less than
35 years of age in 1,585 children between 1996 and 2004 in
the USA has suggested that this should apply to HLA-DR
matching as well. This study, which excluded zero HLA-
mismatched kidneys, showed 5-year graft survival of 71 %
for no mismatches at HLA-DR, 69 % for one mismatch, and
71 % for two mismatches. The conclusion from this review
was that paediatric recipients should be prioritised for such
kidneys and HLA-DR mismatch should be discounted [43].
However, this study is in contradiction to others, including
paediatric studies, which have shown that HLA matching is
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one of the most important influences on outcome. Further-
more, the study did not look at rejection rates or immunosup-
pression requirement and its adverse effects [45]. More re-
cently, the benefits of HLA matching have been very clearly
shown in a much larger adult cohort reported to the Collabo-
rative Transplant Study. For every increase in mismatch there
was a decrease in graft survival (Fig. 2a). This matching effect
also extends to living donation, with a 92 % transplant sur-
vival at 5 years for an HLA-identical sibling and 86% for one-
haplotype donors, compared with 76 % for deceased donors
[5].
Rejection episodes
Much of the poorer outcome of mismatched grafts can be
explained by an increased rate of rejection episodes, which
rises in proportion to the number of mismatches (Fig. 2b). In
turn, the greater immunosuppression requirement is associat-
ed with an increase in complications, including osteoporosis,
hip fractures and death from infection in adult studies, and
non-Hodgkin lymphoma [5]. The latter has been shown to be
two-fold more common with two HLA-DR mismatches in a
study of 9,000 children [46].
Donor-specific HLA antibody development
Approximately two thirds of late graft loss is due to antibody-
mediated rejection. Fifteen to twenty per cent of patients
develop de novo donor-specific HLA antibodies (DSA) by
5 years post-transplant and 50 % of these patients subsequent-
ly lose their grafts within the next 5 years. The primary risk of
developing DSA is the degree of HLA mismatch, particularly
at HLA-DR and -DQ [5, 47, 48]. The risk is compounded by a
reduction of immunosuppression (either in immunosuppres-
sion minimisation protocols or due to complications such as
infections) and by non-adherence [49, 50]. Patients with DSA
towards HLA-DQ are at an increased risk of developing
transplant glomerulopathy, which is often difficult to treat
and progresses to loss of the renal allograft [6, 51]. In our
cohort at Great Ormond Street Hospital, 45 % of DSA-
Fig. 2 a Graft survival according
to human leukocyte antigens
(HLA) mismatches. b Incidence
of rejection according to HLA
mismatches. Data for recipients of
deceased donor transplants and
poorly matched living donors
reported to the Collaborative
Transplant Study, 2000–2010.
Used with permission from Susal
and Opelz [5]
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positive patients had HLA-DQ antibodies (Jon J. Kim, personal
communication, May 2014). HLA-DQmatching is currently not
being performed in renal transplantation but is a consideration
for the future.
Studies looking at the prevention of DSA have focused on
patients receiving blood-group incompatible transplantation
(ABOi) as these patients undergo B-cell depletion with either
splenectomy (historically) or rituximab. The hypothesis is
whether B-cell depletion might remove memory B-cells and
have an immune-educating effect on emerging B-cells after
transplantation. The results from two retrospective cohorts are
conflicting with one showing a reduction in the formation of
de novo DSA and one showing no effect [52, 53]. However,
interim results at 3 years′ follow-up of a randomised control
trial (RCT) of rituximab at induction showed an increasing
trend for DSA formation and a significant increase in mortal-
ity owing to cardiac arrests in the rituximab group [54].
Another RCT had to be aborted early owing to increased rates
of rejection in the rituximab group in the setting of steroid
avoidance [55]. These studies highlight that non-specific de-
pletion of B-cells can be detrimental as it also depletes the
subpopulation of B-cells, which has recently been shown to
play a regulatory role [56]. A third RCT is underway
(ReMIND) [57]. In summary, avoidance of HLAmismatching
and judicious immunosuppression levels are still the best
strategies for the prevention of de novo DSA formation.
Effects of preformed HLA antibodies
An analysis of the US Scientific Registry of Transplant Re-
cipients, which studied 2,704 children relisted for transplant
after a failed graft between 1990 and 2008, found that DR
mismatching at the first transplant resulted in more sensitisa-
tion, a reduced chance of retransplantation with longer waiting
times if retransplant was achieved, and poorer transplant out-
come [40].
Waiting times
The waiting time for a transplant for HLA-sensitised patients
is up to four times longer than that for non-sensitised patients
[41]. As would be expected, this is influenced by the breadth
of HLA sensitisation, as reflected in the reaction frequency. In
the USA, prioritisation of kidneys from donors <35 years of
age for children has sacrificed an increase in HLA sensitisa-
tion for shorter waiting times. The US Scientific Registry of
Transplant Recipients has shown that the reaction frequency
overall increased from a mean of 7 to 55 % after first graft
failure. This figure was 39 % in those who could be
retransplanted, with a waiting time of 19 months, but was
68 % in those who failed to obtain a second transplant during
the study period of 44 months. Two prior HLA-DR mis-
matches significantly increased the waiting time, even in those
who did receive a retransplant (23 months vs 19 months), and
45 % of these patients remained un-transplanted compared
with 29 % in patients with 0–1 DR mismatches [40].
Transplant survival
In an analysis from The US Scientific Registry of Transplant
Recipients of children receiving their second transplant be-
tween 2000 and 2008, those with 2 DRmismatches at first and
second transplant had 5-year graft survival of 47 %, whereas
those with 0–1 DR mismatch had the best at 70 % (Fig. 3).
Although sensitisation had a significant effect, the strongest
association with poor transplant outcome was two DR mis-
matches at both transplants [40]. A further paediatric study has
shown an increased risk of rejection rates, sensitisation and
transplant outcome with DR mismatch [58] and the risk of
sensitisation seems to be greater in younger patients [59].
The presence of DSA pre-transplant is associated with
poorer allograft outcome. In a meta-analysis of 1,119 adult
patients, the presence of DSA despite a negative flow cytom-
etry and CDC cross-match doubled the risk of antibody-
mediated rejection (ABMR) and increased the risk of allograft
failure (relative risk 1.76, confidence interval 1.13–2.74) [60].
In a recent study looking specifically at “spontaneous” DSA,
DSA-positive patients also had higher incidences of ABMR
[61]. However, these episodes responded to treatment and
graft function at 1-year post-transplant was similar. Therefore,
although pre-existing DSAs with negative cross-match are not
a contra-indication to transplantation, patients require close
monitoring for ABMR. Strategies used to desensitise patients
include combinations of IVIG, plasmapheresis, rituximab and
bortezomib [62].
Fig. 3 Graft survival for re-transplantations between 2000 and 2008
segregated by DR mismatches at first and second transplant. Used with
permission from Gralla et al. [40]
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Prevention of HLA sensitisation
Preventing sensitisation from transfusions
The main modifiable risk factor to reduce sensitisation is the
avoidance of blood transfusions. This will require optimisation
of erythropoietin and iron supplementation therapies. Where
unavoidable, transfusions should only be used in emergencies
or for symptomatic treatment rather than using arbitrary
haemoglobin cut-offs for treatment. Close co-operation is also
required from all health care professionals looking after children
with CKD, including surgeons, anaesthetists and intensivists.
In the UK, universal leukodepletion was adopted in 1999.
Leukocytes are filtered and residual counts of <1×106 per unit
are often achieved. The effect of leukodepletion on HLA
sensitisation is controversial and studies have shown similar
rates before and after universal adoption of leukodepleted
blood [24, 42, 63]. In an older study randomising patients to
leukodepleted red cells or non-reduced packed red cells, there
was no benefit to HLA sensitisation, the likelihood of receiv-
ing a graft or graft survival [64]. It is clear, though, that the risk
of HLA sensit isat ion is not entirely negated by
leukodepletion. In the past, short courses of immunosuppres-
sion were used in the setting of a donor-specific transfusion
protocol and this was associated with lower rates of HLA
sensitisation, although this practice is not routinely performed
currently [65, 66]. Additionally, we performed a study looking
at the washing of leukodepleted blood. We have shown
in vitro that the amount of residual leukocytes remains similar
when using a manual wash, and there is only a 33% reduction
when using an automated method. The use of washed cells in
patients has not reduced sensitisation risk either [19].
As HLA matching is performed for platelet-refractory
patients, this practice can in theory be extended to red
blood cells. In a small study, 37 patients were given HLA-
A- and -B-matched blood where possible, and the
HLAMatchmaker programme was used to allocate blood
units from donors considered least likely to stimulate an
immune response [67]. Development of HLA antibodies
was compared with a group of 31 patients who received
randomly selected blood transfusions. In the HLA-
selected group, only 27 % received 0-HLA-A- and -B-
mismatched blood and the rest were allocated by
HLAMatchmaker, identifying the difficulties in obtaining
well-matched blood even just at the class 1 level. How-
ever, none of the patients who received HLA-selected
blood experienced any changes in antibody levels, where-
as 7 of those given randomly selected blood had de novo
HLA antibodies or an increase in panel reactive HLA
antibodies [67]. This study can be interpreted as an effect
of HLA matching or the usefulness of allocating with
HLAMatchmaker but would obviously need a further
randomised controlled trial to determine efficacy.
Even blood given perioperatively can increase ABMR in
patients with preformed HLA antibodies, suggesting that
transfusion might provide additional allostimulation, despite
concomitant immune suppression [68].
Avoidance of HLA mismatches with a high frequency
in the donor population
The most common HLA antigen is HLA-A2, which is found
in almost 50 % of Caucasian people. Ninety per cent of
Caucasians with HLA-A2 have HLA-A*02:01, although oth-
er ethnic groups may have different alleles. Frequencies of
other HLA antigens vary with ethnicity: e.g. HLA-B8 is
present in 30 % of Irish; HLA-B54 is unique to Far Eastern
populations such as Japan; and HLA-A36 is found in the
Black (Afro-Caribbean) population. It may be considered
unwise to mismatch at a common antigen, e.g. HLA-A2,
particularly in children, to avoid sensitisation to half the
potential donors, which would compromise retransplantation.
Bw6 is an epitope shared bymanyHLA-B antigens. Antibody
specificity against the Bw6 epitope is particularly problematic,
as it is found in 86 % of the general population [1, 41].
In the UK, highly sensitised patients (>85 % calculated
reaction frequency) are prioritised for 000 HLA-A-, -B-, -DR-
mismatched grafts in order to reduce waiting times and pro-
long transplant survival [25].
The HLAMatchmaker mentioned above is a program un-
dergoing development that aims to match HLA at the three-
dimensional structural level and examines epitopes that are
exposed on the surface of HLA. This could potentially be used
to further refine HLAmismatches to low or high immunogen-
ic risk or assign acceptable mismatches [69, 70].
Role of weaning of immunosuppression after a failed
transplant
The contribution of nephrectomy and/or continuing immuno-
suppression to HLA sensitisation in the failing graft is not clear.
Transplants that fail in the first year, or those that result from
acute non-concordance with medications often present with
acute rejection and systemic involvement, and frequently prog-
ress to nephrectomy; it is perhaps not surprising, therefore, that
HLA sensitisation is common in this situation [71]. Any possi-
ble benefits of HLA sensitisation by continuation of immuno-
suppression with a failing graft have to be balanced against the
side effects and, in particular, the risk of infection in the patient
on dialysis. One adult study has demonstrated the importance of
continuing immunosuppression. Of 119 adult patients with a
low reaction frequency before transplantation, 56 % of patients
were highly sensitised (class I or II reaction frequency ≥80 %)
at follow-up 6 to 24 months after transplant failure. The per-
centage of those who were highly sensitised increased from
21 % at the time of failure on immunosuppressive therapy to
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68 % after weaning, whereas patients who maintained immu-
nosuppression showed minimal sensitisation after failure.
Transplant nephrectomy was required in 41 % of patients
who were weaned from immunosuppression, but in none of
thosewho continued immunosuppression [72]. However, this is
at the cost of an increased risk of infection. Of 186 patients with
failed transplants, 38 % who had been weaned from their
immunosuppression had infection requiring hospitalisation, in
contrast to 88 % who remained on it. Infections were predom-
inantly dialysis catheter-related. On the other hand there was a
higher incidence of graft nephrectomy in the patients who had
weaned their immunosuppression (81 % vs 30 %) owing to the
development of transplant rejection [73].
The practice of performing nephrectomies for failed trans-
plants varies from centre to centre. The removal of transplants
owing to early failure (<6–12months) has been associated with
a reduction in HLA sensitisation and improvement in subse-
quent transplant outcomes [74, 75]. In contrast, removal of late
failure grafts is associated with an increase in detectable HLA
antibodies [74, 76–78]. The detection of DSA increases to as
high as 81–87 % post-nephrectomy using solid phase arrays
[76, 78]. There are concerns that the failed allograft may serve
as a reservoir absorbing circulating DSA and preventing their
detection, hence the exclusion of previous mismatches from
future transplants [78]. The breadth of HLA reactivity also
increases and in one study, the newly detected HLA antibodies
showed 89 % homology to DSA [74, 76]. The impact of HLA
sensitisation notwithstanding, the decision to perform nephrec-
tomy needs to balance the risks (bleeding, sepsis) against
clinical indications (tenderness and fever, or to create space
for future transplants). Preservation of residual renal function
on dialysis is clearly associated with improved cardiovascular
outcomes [71]. However, the retention of a failed allograft is
also associated with a chronic inflammatory state that can lead
to anaemia, erythropoietin resistance and hypoalbuminaemia
[79]. Studies investigating outcomes on subsequent transplants
have not shown any conclusive differences between
nephrectomised and non-nephrectomised patients [75, 80,
81]. There is, however, a trend towards increased acute rejec-
tion and poorer graft survival in some studies but not in others,
likely because of counter-action from increased immunosup-
pression [80, 82]. In summary, the decision to remove failed
allografts needs to be done on an individual basis and should
only be considered for cases with clear indications. Whilst the
allograft remains in situ, the continuation of low-dose immu-
nosuppression is associated with reduced HLA sensitisation.
Conclusion
Human leukocyte antigen mismatching remains the main
barrier to long-term allograft survival. In an ideal world, organ
allocation programs would take a long-term view to reduce
mismatching in children as they will require more than one
transplant during their lifetime. HLA-DR mismatching in
particular has been shown to reduce graft outcome in subse-
quent transplants. Avoidance of transfusions through the op-
timisation of erythropoietin and iron supplementation remains
the key strategy as the risk of HLA sensitisation, even from
leukodepleted red cells, remains a significant risk. The use of
HLA-matched red cells deserves further studies. In patients
with failed allografts, maintenance of immunosuppression and
avoiding nephrectomy is associated with less HLA sensitisa-
tion, although this has to be balanced against the risks of
infections and a potential chronic inflammatory state. The
development of successful desensitisation programmes may
help to mitigate the problem of HLA sensitisation in the
future.
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Multiple choice questions (answers are provided following
the reference list)
1. Which of the following is true regarding HLA?
a) Red blood cells do not possess HLA.
b) HLA class II is mainly present on antigen-presenting
cells.
c) An example of HLA class II is HLA-G.
d) CD4 T-cells interact with HLA class I to cause cell
lysis.
2. Which of the following patients has the highest risk of
sensitisation?
a) A 6-month-old receiving red cells to prime
haemodialysis lines.
b) A 2-year-old receiving a red blood cell transfusion at
the time of transplantation surgery.
c) A 10-year-old girl on haemodialysis receiving plate-
lets prior to removal of her infected line.
d) A 10-year-old girl with a failed transplant receiving a
red blood cell transfusion following graft
nephrectomy.
3. Which of the following is true regarding HLA-matching
programs for transplantation?
a) The risk of rejection from HLA-A- and -B-
mismatching is negligible.
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b) Patients sensitised to HLA-DR, for example from
previous -DR mismatch in a failed allograft, face
significantly longer waiting times and poorer graft
outcomes.
c) HLA matching is not clinically significant in the
modern immunosuppressive era with the use of B-
cell-depleting agents such as ATG and rituximab.
d) The presence of DSA pre-transplant is not associated
with increased risks of antibody-mediated rejection.
4. What is the most effective practice for preventing HLA
sensitisation?
a) Avoidance of transfusions and optimisation of
erythropoiesis-stimulating agents and iron stores.
b) Using washed red cells for transfusion.
c) Using leukodepleted red cells for transfusion.
d) Using HLA-matched red cells for transfusion.
5. Regarding the management of failed allografts, which of
the following is true?
a) Allograft nephrectomies should be routinely per-
formed as the graft is no longer functioning.
b) Cessation of immunosuppression in the presence of a
failed allograft in situ is not associated with
sensitisation.
c) Nephrectomies are indicated for persisting anaemia
despite optimisation of medical treatment.
d) Nephrectomies should not be performed as they are
liable to absorb antibodies and have been found to
benefit subsequent retransplantation.
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reproduction in any medium, provided the original author(s) and the
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